| Catalog No. |
TD-VK665026 |
| Species reactivity |
Human cytomegalovirus (strain AD169) (HHV-5) (Human herpesvirus 5) |
| Applications |
Research Grade Biosimilar |
| Host species |
Human |
| Isotype |
IgG1, lambda2 |
| Expression system |
Mammalian Cells |
| Clonality |
Monoclonal |
| Target |
Envelope glycoprotein B, gB, UL55 |
| Endotoxin level |
Please contact the lab for this information. |
| Purity |
>95% purity as determined by SDS-PAGE. |
| Purification |
Protein A/G, purified from cell culture supernatant. |
| Accession |
P06473 |
| Form |
Liquid |
| Storage buffer |
0.01M PBS,pH7.4. |
| Stability and Storage |
Use a manual defrost freezer and avoid repeated freeze-thaw cycles. Store at 4°C for short-term storage (1-2 weeks). Store at -20°C for up to 12 months. For long-term storage, store at -80°C. |
| Alternate Names |
NPC21,NPC-21,NPC21,CAS:2467411-25-0 |
| Background |
Fiztasovimab (NPC-21; EV2038) is a fully human IgG1λ mAb against human cytomegalovirus (hCMV). Fiztasovimab acts neutralizing activity by binding to the antigenic domain 1 of glycoprotein B on hCMV envelope. Fiztasovimab inhibits cell-to-cell transmission of hCMV. |
| Note |
For research use only. Not for use in clinical or therapeutic applications. |
抗体
试剂盒
多肽
蛋白
组织芯片
定制服务咨询